PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34619160-0	2021	A network pharmacology approach to investigate the anticancer mechanism of cinobufagin against hepatocellular carcinoma via downregulation of EGFR-CDK2 signaling.	cinobufagin	75-86	cyclin dependent kinase 2	Homo sapiens	147-151	
34619160-5	2021	Inhibition of EGFR or CDK2 expression could not only suppress the growth of tumor cells but also enhance the inhibitory effects of cinobufagin on the proliferative potential of human hepatoma cells.	cinobufagin	131-142	cyclin dependent kinase 2	Homo sapiens	22-26	
34619160-7	2021	Furthermore, EGFR inhibitor gefitinib or CDK2 inhibitor CVT-313 synergistically enhances anticancer effects of cinobufagin in human hepatoma cells.	cinobufagin	111-122	cyclin dependent kinase 2	Homo sapiens	41-45	
34619160-8	2021	Taken together, these findings indicate that cinobufagin may exert antitumor effects by suppressing EGFR-CDK2 signaling, and our study suggests that cinobufagin may be a novel, promising anticancer agent for the treatment of HCC.	cinobufagin	45-56	cyclin dependent kinase 2	Homo sapiens	105-109